Regarding checkpoint inhibitors (PD-1 and PD-L1) and exhaustion markers (TIM3, LAG3, and IDO), which are targets of immunotherapies and thus are also currently of great interest also in mesothelioma research (26), we did not observe any associations with patient survival (Supplementary Table S4) (6, 7). This evidence concerns the gene LAG3 and mesothelioma.